A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
- Conditions
- Metastatic Breast Cancer
- Interventions
- Registration Number
- NCT01989676
- Lead Sponsor
- Pfizer
- Brief Summary
The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280014 in combination with paclitaxel versus trastuzumab sourced from the European Union (trastuzumab-EU) with paclitaxel in female patients with HER2-positive, metastatic breast cancer in the first-line treatment setting. The hypothesis to be tested in this study is that the efficacy (ORR) of PF-05280014 is similar to trastuzumab-EU.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 707
- Histologically confirmed diagnosis of breast cancer.
- Presence of metastatic disease.
- Documentation of HER2 gene amplification or overexpression.
- Available tumor tissue for central review of HER2 status.
- At least 1 measurable lesion as defined by RECIST 1.1.
- Eastern Cooperative Oncology Group status of 0 to 2.
- Left ventricular ejection fraction within institutional range of normal, measured by either two dimensional echocardiogram or multigated acquisition scan.
- Relapse within 1 year of last dose of previous adjuvant (including neoadjuvant) treatment (except endocrine therapy) and within 1 year before randomization.
- Prior systemic therapy for metastatic disease (except endocrine therapy).
- Prior cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose >800 mg/m^2, or the equivalent dose for other anthracyclines or derivatives (eg, 72 mg/m^2 of mitoxantrone). If the patient has received more than one anthracycline, then the cumulative dose must not exceed the equivalent of 400 mg/m^2 of doxorubicin.
- Inflammatory breast cancer.
- Active uncontrolled or symptomatic central nervous system metastases.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-05280014 PF-05280014 - PF-05280014 Paclitaxel - Herceptin® Herceptin® - Herceptin® Paclitaxel -
- Primary Outcome Measures
Name Time Method Objective Response Rate (ORR) Derived From Central Radiology Assessments: ITT Population From the date of randomization until all participants had either completed the Week 33 tumor assessment or discontinued study drug earlier than the Week 33 visit ORR was defined as the percentage of participants who achieved complete response (CR, complete disappearance of all target lesions with the exception of nodal disease; all target nodes must have decreased to normal size \[short axis \<10 mm\]) or partial response (PR, \>=30% decrease from baseline of the sum of diameters (SOD) of all target measurable lesions; the short diameter was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions) by Week 25 of the study and confirmed on a follow-up assessment (Week 33+/-14 days), based on the assessments of the central radiology review in accordance with RECIST 1.1.
- Secondary Outcome Measures
Name Time Method Serum Peak Concentration of PF-05280014 at Selected Cycles: Pharmacokinetics (PK) Population 1 hour post end of infusion on Day 1 of Cycles 1 and 5 Human PK serum samples were analyzed for concentrations of PF-05280014 using a validated, sensitive, and specific enzyme-linked immunosorbent assay (ELISA).
Serum Peak Concentration of Trastuzumab-EU at Selected Cycles: PK Population 1 hour post end of infusion on Day 1 of Cycles 1 and 5 Human PK serum samples were analyzed for concentrations of trastuzumab-EU using a validated, sensitive, and specific ELISA.
One-year Progression-Free Survival (PFS) Rate Derived From Central Radiology Assessments: ITT Population From the date of randomization until 378 days post-randomization One-year PFS rate was analyzed based on the time from date of randomization to first documentation of progressive disease (PD), or death due to any cause in the absence of documented PD, based on the assessments of the central radiology review in accordance with RECIST 1.1. PD was defined for target disease as at least a 20% increase in sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum was observed during therapy) with a minimum absolute increase of 5 mm. For non-target disease: PD was defined as unequivocal progression of pre-existing lesions and if overall tumor burden increased sufficiently to merit discontinuation of therapy; appearance of any new unequivocal malignant lesion was also considered PD. The 95% CI for the median time to event was based on the Brookmeyer and Crowley method.
Duration of Response (DOR) Per Central Radiology Assessments: ITT Population From the date of randomization until 378 days post-randomization DOR:time from first documentation of objective response (CR or PR) to first documentation of PD/death due to any cause in absence of documented PD, based on central radiology review. As per RECIST v1.1, CR:complete disappearance of all target lesions with exception of nodal disease; all target nodes reduced in short axis \<10 mm. PR: \>=30% decrease from baseline of SOD of target lesions; short diameter used in sum for target nodes,longest diameter used in sum for other target lesions. PD for target disease:at least 20% increase in SOD of target lesions above smallest sum observed (over baseline if no decrease in sum observed) with minimum absolute increase of 5 mm. For non-target disease:unequivocal progression of pre-existing lesions and if overall tumor burden increased sufficiently to merit discontinuation of therapy; appearance of any new unequivocal malignant lesion was also considered PD. The 95% CI for median time to event was based on the Brookmeyer and Crowley method.
Overall Survival: ITT Population From the date of randomization until end of study (approximately 6 years) Overall survival was analyzed based on the time from date of randomization to the date of death due to any cause. Participants last known to be alive were censored on the date of last contact. The 95% CI for the median time to event was based on the Brookmeyer and Crowley Method.
Serum Trough (Pre-dose) Concentration of PF-05280014 at Selected Cycles: PK Population Pre-dose on Day 1 of Cycles 1, 3, 4, 5, 7, 8, 11, 14, 17 and Day 8 of Cycles 1 and 5 Human PK serum samples were analyzed for concentrations of PF-05280014 using a validated, sensitive, and specific ELISA.
Serum Trough (Pre-dose) Concentration of Trastuzumab-EU at Selected Cycles: PK Population Pre-dose on Day 1 of Cycles 1, 3, 4, 5, 7, 8, 11, 14, 17 and Day 8 of Cycles 1 and 5 Human PK serum samples were analyzed for concentrations of trastuzumab-EU using a validated, sensitive, and specific ELISA.
Number of Participants With Positive Neutralizing Antibodies (Nab) Prior to Treatment: Safety Population Cycle 1 Day 1 (prior to treatment) Human serum samples testing positive for the presence of ADA (anti-PF-05280014 or anti-trastuzumab-EU) were analyzed for the presence or absence of NAb (neutralizing anti-PF-05280014 or neutralizing anti-trastuzumab-EU antibodies) following a tiered approach using screening and titer determination. The number of participants at baseline (prior to treatment) with a positive NAb sample (titer \>=1.48) is provided.
Number of Participants With Positive Anti-Drug Antibodies (ADA) Sample: Safety Population Pre-dose on Day 1 of Cycles 1, 3, 5, 8, 11, 14, 17 Two sensitive, specific, and semi-quantitative electrochemiluminescent (ECL) immunoassays, 1 for detecting antibodies against PF-05280014 and the other for detecting antibodies against trastuzumab, were used to analyze ADA samples. Serum samples were first screened for ADA. Any samples that were positive in the screening assay were further analyzed to confirm the positive result and determine the antibody titers. All samples were taken prior to dosing. The number of participants with a positive sample (titer \>=1.0) is provided.
Trial Locations
- Locations (180)
Municipal Institution Odesa Regional Clinical Hospital, Mammology Center
🇺🇦Odesa, Ukraine
Municipal Institution "Chernivtsi Regional Clinical Oncology Center", Outpatient Department
🇺🇦Chernivtsi, Ukraine
Zakarpattia Regional Clinical Oncological Center
🇺🇦Uzhgorod, Ukraine
Municipal Non-Profit Enterprise of Kyiv Regional Council "Kyiv Regional Oncology Dispensary"
🇺🇦Kyiv, Ukraine
Acharya Tulsi Regional Cancer Treatment and Research Institute
🇮🇳Bikaner, Rajasthan, India
National Cancer Institute
🇹🇭Ratchathewi, Bangkok, Thailand
Cancer Center of Central Connecticut
🇺🇸Southington, Connecticut, United States
Hospital Naval Almirante Nef
🇨🇱V Region, Chile
Hospital Clinico Vina Del Mar
🇨🇱Vina del Mar, V Region, Chile
Instituto do Cancer de Londrina - Hospital do Cancer de Londrina - HCL
🇧🇷Londrina, Parana, Brazil
Florida Cancer Research Institute
🇺🇸Plantation, Florida, United States
Hakuaikai Medical Corporation Sagara Hospital
🇯🇵Kagoshima, Japan
Clinica Alemana de Temuco
🇨🇱Temuco, Region DE LA Araucania, Chile
Meenakshi Mission Hospital and Research Centre
🇮🇳Madurai, Tamil NADU, India
LLC VitaMed
🇷🇺Moscow, Russian Federation
Institutul Oncologic Prof. Dr. Ion Chiricuta
🇷🇴Cluj-Napoca, Cluj, Romania
Spitalul Judetean de Urgenta "Sf.Ioan cel Nou", Sectia Oncologie
🇷🇴Suceava, Romania
Oncology Institute of Vojvodina
🇷🇸Sremska Kamenica, Serbia
Republic Clinical Hospital of Emergency Care
🇷🇺Grozny, Chechenkaya Republic, Russian Federation
Municipal Non-Profit Enterprise City Clinical Hospital No.4of Dnipro Regional Council, Department of
🇺🇦Dnipro, Ukraine
Advanced Centre for Treatment Research and Education in Cancer (ACTREC)
🇮🇳Navi Mumbai, Maharashtra, India
Spitalul Clinic Municipal de Urgenta Timisoara, Sectia Clinica Oncologie Medicala
🇷🇴Timisoara, Romania
Faculty of Medicine, Chulongkorn University, Medical Oncology Unit
🇹🇭Bangkok, Thailand
Shatabdi Super Speciality Hospital
🇮🇳Nashik, Maharashtra, India
Acharya Harihar Regional Cancer Center
🇮🇳Cuttack, Odisha, India
Instituto Nacional de Cancerologia
🇲🇽Mexico City, Distrito Federal, Mexico
Instituto Oncologico Clinica Renaca
🇨🇱V Region, Chile
Centro de Investigacion Clinica SIM
🇨🇱Temuco, Region DE LA Araucania, Chile
Cancerologia de Queretaro S.C.
🇲🇽Queretaro, Mexico
Tata Memorial Centre, Tata Memorial Hospital
🇮🇳Mumbai, Maharashtra, India
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
🇯🇵Bunkyo-ku, Tokyo, Japan
Oaxaca Site Management Organization S.C.
🇲🇽Oaxaca, Mexico
National Hospital Organization Tokyo Medical Center
🇯🇵Meguro-Ku, Tokyo, Japan
Consultorio dentro de la Torre Medica Dalinde (Oncologia Medica)
🇲🇽Mexico, Distrito Federal, Mexico
SC Oncolab SRL, Oncologie
🇷🇴Craiova, Jud Dolj, Romania
Siglo XXI
🇵🇪Lima, Peru
Cebu Doctors' University Hospital
🇵🇭Cebu City, Cebu, Philippines
The Research Institute at Perpetual Succor Hospital
🇵🇭Cebu City, Region VII, Philippines
University of Philippines Manila-Philippine General Hospital
🇵🇭Manila, NCR, Philippines
Udonthani Cancer Hospital
🇹🇭Amphur Muang, Udonthani, Thailand
State Budgetary Healthcare Institution "Leningrad Regional Oncological Dispensary"
🇷🇺Kuzmolovo, Vsevolozhskiy, Leningrad Region, Russian Federation
State Budgetary Healthcare Institution ''Republic Oncological Dispensary''
🇷🇺Petrozavodsk, Republic OF Karelia, Russian Federation
State Budgetary Healthcare Institution "Chelyabinsk Regional Clinical Oncological Dispensary"
🇷🇺Chelyabinsk, Russian Federation
Rostov Research Institute of Oncology
🇷🇺Rostov-on-Don, Rostov Region, Russian Federation
SBIH of Kaluga Region "Kaluga Regional Clinical Oncology Dispensary"
🇷🇺Kaluga, Russian Federation
State Budgetary Healthcare Institution of Stavropol region "Stavropol regional clinical oncology
🇷🇺Stavropol, Russian Federation
Markusovszky Egyetemi Oktatokorhaz
🇭🇺Szombathely, Hungary
COIBA - Centro de Oncologia e Investigacion Buenos Aires
🇦🇷Berazategui, Buenos Aires, Argentina
Instituto De Oncologia De Rosario
🇦🇷Rosario, Santa FE, Argentina
Sanatorio de la Providencia
🇦🇷C.a.b.a, Argentina
Centro Medico San Roque
🇦🇷San Miguel de Tucuman, Tucuman, Argentina
CRIO - Centro Regional Integrado de Oncologia
🇧🇷Fortaleza, CE, Brazil
Associacao de Combate ao Cancer em Goias - Hospital Araujo Jorge
🇧🇷Goiania, GO, Brazil
Associacao Hospital de Caridade Ijui
🇧🇷Ijui, RS, Brazil
Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner
🇧🇷Curitiba, Parana, Brazil
Hospital Bruno Born (Sociedade Beneficencia e Caridade de Lajeado)
🇧🇷Lajeado, RIO Grande DO SUL, Brazil
Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia
🇧🇷Porto Alegre, RS, Brazil
Fundacao Pio XII - Hospital de Cancer de Barretos
🇧🇷Barretos, SAO Paulo, Brazil
Administrative office
🇨🇱Temuco, Region DE LA Araucania, Chile
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC
🇧🇷Santo Andre, SP, Brazil
Centro de Pesquisas Oncologicas de Santa Catarina - CEPON
🇧🇷Florianopolis, SC, Brazil
Fresenius Kabi Chile Therapia iv
🇨🇱Santiago, RM, Chile
Instituto Oncologico, Clinica Renaca
🇨🇱Vina del Mar, V Region, Chile
Onkologicka klinika VFN a 1. LF UK, Fakultni poliklinika
🇨🇿Praha 2, Czechia
General Hospital of Chania "O Agios Georgios"
🇬🇷Chania, Crete, Greece
Interbalkan European Medical Center
🇬🇷Pylaia, Thessaloniki, Greece
General Hospital of Athens "Hippokration"
🇬🇷Athens, Greece
Borsod-Abauj-Zemplen Megyei Korhaz, es Egyetemi Oktatokorhaz, Klinikai Onkologiai es Sugarterapias
🇭🇺Miskolc, Hungary
Bacs-Kiskun Megyei Korhaz, Onkoradiologiai Kozpont
🇭🇺Kecskemet, Hungary
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet, Megyei Onkologiai Kozpont
🇭🇺Szolnok, Hungary
Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral
🇧🇷Itajai, SC, Brazil
Manipal Hospital
🇮🇳Bengaluru, Karnataka, India
Department of Medicine New Block
🇮🇳Visakhapatnam, Andhra Pradesh, India
Manipal Centre for Clinical Research
🇮🇳Manipal, Karnataka, India
Deenanath Mangeshkar Hospital & Research Centre
🇮🇳Pune, Maharashtra, India
Sahyadri Speciality Hospital
🇮🇳Pune, Maharashtra, India
Sahyadri Clinical Research & Development Centre
🇮🇳Pune, Maharashtra, India
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka-Shi, Fukuoka, Japan
Japan Community Health care Organization Kurume General Hospital
🇯🇵Kurume-city, Fukuoka, Japan
National Hospital Organization Nagoya Medical Center
🇯🇵Nagoya, Aichi, Japan
MNJ Institute of Oncology & Regional Cancer Center
🇮🇳Hyderabad, Telangana, India
Kumamoto University Hospital
🇯🇵Kumamoto-city, Kumamoto, Japan
Saitama Cancer Center Hospital
🇯🇵Kitaadachi-gun, Saitama, Japan
Showa University Hospital
🇯🇵Shinagawa-ku, Tokyo, Japan
Chiba Cancer Center
🇯🇵Chiba, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Nakanoshima Osaka Breast Clinic
🇯🇵Osaka, Japan
Osaka Breast Clinic
🇯🇵Osaka, Japan
Shizuoka General Hospital
🇯🇵Shizuoka, Japan
Ulsan University Hospital
🇰🇷Ulsan, Korea, Korea, Republic of
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Kyungpook National University Chilgok Hospital
🇰🇷Daegu, Korea, Republic of
National Cancer Centre
🇰🇷Goyang-si, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
P.Stradins Clinical University Hospital
🇱🇻Riga, Latvia
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Inter Hosp S.A. de C.V. "Centro Medico Dalinde"
🇲🇽Mexico, Distrito Federal, Mexico
INNPARES
🇵🇪Lima, Peru
Resocentro
🇵🇪Lima, Peru
Instituto de Oncologia y Radioterapia de la Clinica Ricardo Palma
🇵🇪Lima, Peru
Instituto Nacional de Enfermedades Neoplasicas
🇵🇪Lima, Peru
Cardinal Santos Medical Center
🇵🇭San Juan City, Mentro Manila, Philippines
Clinica Anglo Americana
🇵🇪Lima, Peru
Radiologos S.R.L.
🇵🇪Lima, Peru
Manila Doctors Hospital
🇵🇭Manila, Philippines
Veterans Memorial Medical Center
🇵🇭Quezon City, Metro Manila, Philippines
The Medical City
🇵🇭Pasig City, NCR, Philippines
St. Luke's Medical Center
🇵🇭Quezon City, NCR, Philippines
COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii
🇵🇱Gdansk, Poland
Centrum Terapii Wspolczesnej
🇵🇱Lodz, Poland
Szpitale Pomorskie Sp. z o.o. Oddzial Onkologii i Radioterapii
🇵🇱Gdynia, Poland
Magodent Sp. z o.o. Oddzial Onkologii Klinicznej/Chemioterapii
🇵🇱Warszawa, Poland
Hospital de Braga
🇵🇹Braga, Portugal
Hospital CUF Descobertas
🇵🇹Lisboa, Portugal
S.C. Medisprof S.R.L
🇷🇴Cluj-Napoca, Cluj, Romania
Centrul de Oncologie Sf. Nectarie
🇷🇴Craiova, Dolj, Romania
Spitalul Universitar de Urgenta, Departamentul Oncologie Medicala
🇷🇴Bucuresti, Romania
Spitalul Clinic Judetean de Urgenta Sibiu
🇷🇴Sibiu, Romania
State Healthcare Institution Kursk Regional Oncological Dispensary of the Healthcare Committee
🇷🇺Kislino Settlement, Kursk, Russian Federation
FSBSI Russian Cancer Research Center n.a. N.N.Blokhin
🇷🇺Moscow, NAP, Russian Federation
Federal State Budgetary Institution ¿National Medical Research Oncology Centre named after N.N.
🇷🇺Saint-Petersburg, Pos.pesochny, Russian Federation
State Healthcare Institution, Republican Clinical Oncology Dispensary of the Ministry of
🇷🇺Ufa, Republic OF Bashkortostan, Russian Federation
State budget institution of healthcare of Mordovia Republic "Republic Oncology Dispensary"
🇷🇺Saransk, Republic OF Mordovia, Russian Federation
Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology)
🇷🇺Poselok Pesochny, Saint-petersburg, Russian Federation
Private medical institution Euromedservice
🇷🇺Pushkin, Saint Petersburg, Russian Federation
LLC Medekspert
🇷🇺Kislovodsk, Stavropol Region, Russian Federation
Federal State Budgetary Healthcare Institution of "Clinical Hospital #101 of Federal Medical and
🇷🇺Lermontov, Stavropol Region, Russian Federation
State Budgetary Healthcare Institution of Stavropol Region Pyatigorsk Oncology Dispensary
🇷🇺Pyatigorsk, Stavropol Region, Russian Federation
Centre of Specialized kinds of Medical Care of Pyatigorsk city
🇷🇺Pyatigorsk, Stavropol Region, Russian Federation
LLC Novaya Clinica
🇷🇺Pyatigorsk, Stavropol Region, Russian Federation
Pyatigorsk City Hospital #2
🇷🇺Pyatigorsk, Stavropol Region, Russian Federation
Stavropol Regional Hospital for War Veterans
🇷🇺Pyatigorsk, Stavropol Region, Russian Federation
GBUZ Arkhangelsk Regional Clinical Oncological dispensary
🇷🇺Arkhangelsk, Russian Federation
State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary
🇷🇺Volzhskiy, Volgograd Region, Russian Federation
"Regional Budgetary Healthcare Institution ""Ivanovo Regional Oncology Dispensary"""
🇷🇺Ivanovo, Russian Federation
GBUZ "Regional Oncology Dispensary #2"
🇷🇺Magnitogorsk, Russian Federation
Federal State Budgetary Institution "Russian Oncological Scientific Center n.a. N.N. Blokhin" of
🇷🇺Moscow, Russian Federation
Budgetary Institution of Healthcare of Orel region "Orel oncological dispensary"
🇷🇺Orel, Russian Federation
SBEI of HPE "First Saint Petersburg State Medical University
🇷🇺Saint Petersburg, Russian Federation
SBEI HPE RyazSMU of MoH of the Russian Federation based on SBI of Ryazan Region "Regional CLinical
🇷🇺Ryazan, Russian Federation
Non-state healthcare agency Road Clinical Hospital PLC Russian Railways
🇷🇺Saint-Petersburg, Russian Federation
SBI "North-Western State Medical University n.a. I. I. Mechnikov" of the MoH of the Russian
🇷🇺Saint-Petersburg, Russian Federation
Military Medical Academy
🇷🇸Belgrade, Serbia
Saint-Petersburg State Budgetary Healthcare Institution "Oncological Dispensary of Moscow District"
🇷🇺Saint-Petersburg, Russian Federation
Non-State Healthcare Institution "Road Clinical Hospital at Saratov II Station"
🇷🇺Saratov, Russian Federation
Institute for Oncology and Radiology of Serbia
🇷🇸Belgrade, Serbia
Clinic of Oncology-Clinical Center Nis
🇷🇸Nis, Serbia
GVI Oncology, Langenhoven Drive Oncology Centre
🇿🇦Port Elizabeth, Eastern CAPE, South Africa
Onkologicky ustav sv. Alzbety, s.r.o.
🇸🇰Bratislava, Slovakia
Narodny Onkologicky Ustav
🇸🇰Bratislava, Slovakia
Sandton Oncology Centre
🇿🇦Johannesburg, Gauteng, South Africa
wits Clinical Research
🇿🇦Joannesburg, Gauteng, South Africa
The Medical Oncology Centre of Rosebank
🇿🇦Johannesburg, Gauteng, South Africa
*Department of Medical Oncology, University of Pretoria & Steve Biko Academic Hospitals Complex
🇿🇦Pretoria, Gauteng, South Africa
Cape Town Oncology Trials
🇿🇦Kraaifontein, Western CAPE, South Africa
Eastleigh Breast Care Centre
🇿🇦Pretoria, Gauteng, South Africa
GVI Rondebosch Oncology Centre-Rondebosch Medical Centre
🇿🇦Rondebosch, Western CAPE, South Africa
Baskent University School of Medicine Adana Hospital
🇹🇷Adana, Turkey
Hacettepe Universitesi Tip Fakultesi
🇹🇷Ankara, Turkey
Gaziantep University Medical Faculty
🇹🇷Gaziantep, Turkey
Uludag Universitesi Tip Fakultesi Ic Hastaliklari Anabilim Dali
🇹🇷Bursa, Turkey
Dicle University Medical Faculty
🇹🇷Diyarbakir, Turkey
Istanbul Universitesi Onkoloji Enstitusu
🇹🇷Istanbul, Turkey
Khmelnytskyi Regional Oncologic Dispensary
🇺🇦Khmelnytskyi, Ukraine
Communal Non-Profit Enterprise "Regional Center of Oncology"
🇺🇦Kharkiv, Ukraine
Municipal Enterprise 'Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council'
🇺🇦Kryvyi Rih, Ukraine
Lviv State Oncologic Regional Treatment and Diagnostic Center
🇺🇦Lviv, Ukraine
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Chungbuk National University Hospital
🇰🇷Cheongju-si, Chungcheongbuk-do, Korea, Republic of
GBUZ of Perm region "Perm regional oncology dispensary"
🇷🇺Perm, NAP, Russian Federation
Republican Clinical Oncology Dispensary of the Ministry of Healthcare of Baskortostan Republic
🇷🇺Ufa, Republic OF Baskortostan, Russian Federation
GBUZ Republican Clinical Hospital n.a. G.F. Kuvatova
🇷🇺Ufa, Republic OF Baskortostan, Russian Federation
State Budgetary Healthcare Institution "Nizhniy Novgorod Regional Oncological Dispensary"
🇷🇺Nizhniy Novgorod, Russian Federation
"BIH of Omsk Region ""Clinical oncological dispensary"""
🇷🇺Omsk, Russian Federation
SPZOZ MSW z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Oddzial Kliniczny Chemioterapii
🇵🇱Olsztyn, Poland
MRUKMED. Lekarz Beata Madej Mruk i Partner. Sp. p. Oddzial nr 1 w Rzeszowie
🇵🇱Rzeszow, Poland
Municipal Non-profit Enterprise Podilsk Regional Oncology Centre of Vinnytsia Regional Council
🇺🇦Vinnytsia, Ukraine
SI Institute of Medical Radiology n.a.S.P. Ilrygoriev of National Academy of Medical Science of
🇺🇦Kharkiv, Ukraine
Hospital Militar Central
🇵🇪Lima, Peru